Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090532 · ClinicalTrials.gov registry record · Phase 1
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT00090532 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 155 participants.
The verdict
NCT00090532, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.
Interventions
- DRUG AG-013,958
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090532
The ClinicalTrials.gov registry entry for NCT00090532 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-013,958 is the first listed.
NCT00090532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090532 about?
NCT00090532 is a clinical study titled "A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration". AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.
What is the current status of trial NCT00090532?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2004-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00090532?
The interventions under investigation include: AG-013,958 (DRUG).
Who is sponsoring clinical trial NCT00090532?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.